Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman Underscores Firm Stance On Creating Public Insurance Plan In Health Reform Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

House Commerce Committee Chairman Waxman dismisses idea of cooperative insurance as an alternative.

You may also be interested in...



House Reform Bill Gives HHS Rx Price Negotiating Power Through Public Plan

Democrats have found a vehicle for giving the government the ability to directly negotiate drug prices with manufacturers: the public health insurance plan envisioned in the draft reform bill by three House committees

“Co-op Insurance” Emerges As Alternative To Health Reform Public Plan, But What Is It?

Republicans are reportedly open to providing a cooperative insurance plan as an alternative to a public plan as part of the expansion of health care coverage.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel